Cell Bank

Cell Bank designates a collection of vials containing uniform cell populations preserved under controlled conditions, serving as the foundation for consistent biopharmaceutical manufacturing by providing traceable, characterised cell sources for production operations. These frozen repositories exist in tiered systems including master cell banks (MCB) created from single selected clones and working cell banks (WCB) derived from MCB vials, ensuring manufacturing continuity over years or decades without genetic drift or contamination. Cell banking systems incorporate comprehensive testing protocols verifying identity, purity, stability, and absence of adventitious agents before releasing vials for manufacturing use.

The biopharmaceutical industry relies fundamentally on cell banking infrastructure for producing recombinant proteins, monoclonal antibodies, vaccines, and viral vectors. Establishing cell banks requires rigorous qualification including sterility testing, mycoplasma detection, virus screening, identity confirmation through genetic and phenotypic methods, and stability assessment demonstrating consistent performance across passage levels. Regulatory agencies mandate extensive cell bank characterisation data in marketing applications. Companies maintain multiple storage locations providing redundancy against facility failures, natural disasters, or equipment malfunctions. Regulatory guidelines from FDA, EMA, and ICH provide frameworks for cell bank establishment, testing, and storage. As production demands increase and novel cell lines emerge including human cell substrates for gene therapy vectors, cell banking practices continue evolving to address new challenges while maintaining the fundamental principle that well characterised, stable cell sources ensure consistent, safe therapeutic production.